Tests KRT-232 with acalabrutinib in adults with returned lymphoma or leukemia
Tests KRT-232 with acalabrutinib in adults whose lymphoma or leukemia has returned.
Plain-language title generated from the registry record
Registry title: Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
Key facts
- Where
- Edegem, Hasselt, and Leuven, BelgiumSee the 3 sites
- Phase
- Phase 1/2
Where in Belgium
- Antwerp University Hospital (UZA)Edegem, BelgiumTaking people
- JESSA ZiekenhuisHasselt, BelgiumTaking people
- University Hospital (UZ) LeuvenLeuven, BelgiumTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Kartos Therapeutics, Inc.
- Trial code
- NCT04502394
- Record updated
- 4 August 2022
- Original description
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, combined with acalabrutinib for the treatment of adults with Diffuse Large B-Cell Lymphoma and Chronic Lymphocytic Leukemia. Participants must be relapsed/refractory (having failed prior therapy)Read full original descriptionShow less
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma or Relapsed/Refractory Chronic Lymphocytic Leukemia
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, combined with acalabrutinib for the treatment of adults with Diffuse Large B-Cell Lymphoma and Chronic Lymphocytic Leukemia. Participants must be relapsed/refractory (having failed prior therapy)
Inclusion: Cohort 1: Confirmed diagnosis of TP53wt DLBCL (WHO); R/R DLBCL after at least 2 prior lines of treatment or 1 prior for patients who are ineligible for stem cell transplant; Cohort 2: Confirmed diagnosis of TP53wt CLL (iwCLL); R/R CLL after at least 1 prior line of treatment; ECOG 0 to 2; Adequate hematologic, hepatic, and renal functions.
Exclusion: Prior treatment with any MDM2 inhibitor; Prior treatment with any BTK inhibitor.